The QualityStocks Daily Monday, July 30th, 2018

Today's Top 3 StockMarketWatch

Damn Good Penny Picks (ERRCF) +71.79%

StockMarketWatch (SSLJ) +61.48%

MarketBeat (CRMD) +37.25%

The QualityStocks Daily Stock List

Saker Aviation Services, Inc. (SKAS)

TradeKing, Zacks, PennyStocks24, AwesomeStocks, Chatter Box Stocks, SquawkBoxStocks, and TerrificPennyStocks reported previously on Saker Aviation Services, Inc. (SKAS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Saker Aviation Services, Inc. serves as the operator of a heliport, a fixed base operation (FBO), and as a consultant for a seaplane base that it does not own. The Company specializes in ground-based services to the general aviation market. Its dedication is to providing concierge-level aviation services for individuals and corporate clients with a focus on safety. A Nevada corporation, Saker Aviation Services has its corporate office in New York City.

The Company established on January 17, 2003. Saker became a public company due to a reverse merger transaction on August 20, 2004. On September 2, 2009, the Company changed its name to Saker Aviation Services, Inc. Its common stock is publicly traded on the OTC Markets’ OTCQB.

The Company has locations in the Northeast and Midwest. Regarding FBOs, these provide ground-based services. This includes fueling and aircraft storage for general aviation, commercial and military aircraft, and other miscellaneous services. Saker’s set of full service FBOs can provide a fast-turn or complete concierge amenities and reservations.

Saker Aviation Services is an Avfuel branded dealer. Avfuel Corp. is the nation's top independent supplier of aviation fuels and services. Moreover, Saker has an experienced maintenance, concierge, and charter staff. The Company assists its clients with all their aircraft management needs.

Saker JRB is located at the base of Wall Street, above the Battery on Pier 6, on the East River north of the Staten Island Ferry and south of the South Street Seaport. This Downtown Manhattan Heliport is one of the most advanced heliports in the industry. Its focus is user comfort and convenience.

Saker JRB has ramp parking that accommodates helicopters up to 50,000 pounds. Its terminal provides a VIP lounge, flight operations, as well as general administrative office space. The heliport provides services for the world’s most prestigious multinational corporations, trading organizations, and legal firms in Manhattan. This is in addition to it offering sightseeing tours each day.

Saker has acquired Aircraft Services, Inc. in Garden City, Kansas. Its wholly-owned subsidiary, FBO Air Garden City, Inc. (GCK), entered into a Stock Purchase Agreement, dated October 3, 2016, by and between GCK and Gary and Kim Keller, to buy all the capital stock of Aircraft Services, Inc. - an aircraft maintenance services business.

This past May, Saker Aviation Services announced its financial results for the three months ended March 31, 2017. Revenue and Net Loss in the three months ended March 31, 2017 of $2,041,261 and $152,119, respectively, were down 31.2 percent and $338,485, respectively, versus Revenue of $2,967,080 and Net Income of $186,366 in the three months ended March 31, 2016. 

Mr. Ron Ricciardi, President of Saker Aviation Services, said, "The first quarter of 2017 was challenging, as anticipated. The final phase of air tour reductions, which occurred on January 1st and is now at the full 50 percent, was the primary driver of our results.  The reductions are targeted against 2015 activity while Q1 2016 enjoyed full and unfettered activity, which negatively impacted the year-over-year comparisons.  In fact, Q1 2016 tour activity exceeded 2015 by over 36 percent.  Further burdening results was the Easter holiday, which occurred in Q1 in 2016 but in Q2 in 2017. Given that these are extraordinary factors, we anticipate that future quarters will not be influenced to the same extent as Q1, though the reductions will continue to challenge year-over-year comparisons."

Saker Aviation Services, Inc. (SKAS), closed Monday's trading session at $0.0997, up 10.78%, on 16,500 volume with 5 trades. The average volume for the last 60 days is 31,934 and the stock's 52-week low/high is $0.20/$0.76.


Greystone Logistics, Inc. (GLGI)

Zacks, MarketWatch, and Trading View reported on Greystone Logistics, Inc. (GLGI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Greystone Logistics, Inc. reprocesses and sells recycled plastic, and designs, manufactures, sells, and leases high-quality 100 percent recycled plastic pallets. These provide logistical solutions needed by a wide variety of industries. These industries include food and beverage, agricultural, automotive, chemical, and pharmaceutical and consumer products. Greystone Logistics is the largest 100 percent recycled plastic pallet manufacturer in the United States. A "Green" manufacturing and leasing enterprise, Greystone Logistics is headquartered in Tulsa, Oklahoma.

The Company’s technology, including that utilized in its injection molding equipment, and its proprietary blend of recycled plastic resins and patented pallet designs, enables fast production of high-quality pallets and at lower costs than many processes. The recycled plastic for its pallets helps control material costs. This is while lessening environmental waste.

Greystone Logistics provides cost advantages over users of virgin resin. The excess plastic not used in the production of pallets undergoes reprocessing for resale. The Company’s products include rackable, nestable, display, monoblock, as well as stackable pallets. In addition, its products include picture frame web-top pallets and web-top pallets. Furthermore, the Company sells recycled plastic that undergoes reprocessing into pellet form. It also provides pallet leasing services.

Concerning obtaining or selling resin or excess plastic, Greystone Logistics buys HDPE scrap, pellets, purchings, dust, shavings, and parts. The Company sometimes sells some excess pelletized Santoprene, HDPE and comingled-baled scrap TPU and ABS car bumpers.

Greystone Logistics offers recycled pallets for sale including full picture frame and three skids models and IBC pallets. Plastic pallets last 10-50 times longer than wood; have residual (trade-in) value; are recyclable; have a high coefficient of friction with anti-skid design for top, bottom, and fork lift tine contact; have considerably lower life cycle costs (cost per trip), and are suited for closed loop systems. Plastic pallets have no exposed nails, wood chips, or broken boards on manufacturing or warehouse floors. This prevents fork lift issues.

This past April, Greystone Logistics reported that sales for the three months ended February 28, 2017 totaled $8,693,851 versus $5,280,480 for the prior period. This represents an increase of $3,413,371, or 65 percent.

Sales for the nine months ended February 28, 2017 were $25,759,823 versus $15,270,671 for the prior period. This represents an increase of $10,489,152, or 69 percent. The Company said in April that there continues to be a backlog of sales for a wide range of its products.

Greystone Logistics, Inc. (GLGI), closed Monday's trading session at $0.47, up 4.42%, on 22,999 volume with 3 trades. The average volume for the last 60 days is 26,790 and the stock's 52-week low/high is $0.336/$0.60.


Empire Petroleum Corp. (EMPR)

Nebula Stocks reported earlier on Empire Petroleum Corp. (EMPR), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Empire Petroleum Corp. involves in the exploration and development of oil and gas interests in North America. It owns interest in the Gabbs Valley prospect and interest in the South Okie prospect. The Gabbs Valley prospect is an area of about 34,186 gross acres in Nye and Mineral Counties, Nevada. The South Okie prospect encompasses 110 net acres of oil and gas leases in Natrona County, Wyoming.

The Company previously went by the name Americomm Resources Corp. It changed its corporate name to Empire Petroleum Corp. in August of 2001. The Company operates in the Independent Oil & Gas industry in the Basic Materials sector.

Formed in 1983, Empire Petroleum is based in Tulsa, Oklahoma. In February of this year, Empire Petroleum announced it was approved to upgrade its common shares from the Pink® Open Market to the OTCQB® Venture Market under the trading symbol “EMPR”, effective January 30, 2017.

Empire Petroleum has conducted wide-ranging geological studies, conducted a seismic survey, carried out a geochemical imaging survey, conducted satellite and gravity studies and drilled two test wells on the Gabbs Valley Prospect. The additional studies of such data and the assistance of geological and engineering consultants led the Company to conclude that more drilling was warranted. The determination was that a new test well should be drilled using a different method of drilling.

Empire Petroleum drilled the Paradise Unit 2-12 well to a depth of 4,250 feet before drilling problems caused them to halt drilling. The Company recovered small amounts of oil containing paraffin that may have been restricting the oil flow. Swab tests failed to increase the oil flow and Empire suspended operations on the well.

The Company assigned the lease and the 1-12 and 2-12 wells to the other leasehold owners from which Empire had taken a farmout. Empire Petroleum does feel the prospect has significant geological merit since the main target, being the Triassic formation, was not reached in either of the two test wells.

Empire Petroleum and Sierra Nevada Oil, LLC centered their activities on the exploration and development of around 36,750 acres of Bureau of Land Management (BLM) leases situated on a surface anticline in Gabbs, Nevada. Three exploratory wells were drilled on the leases.

Empire Petroleum announced in December of last year, that it entered into an Agreement (Contribution Agreement) with Masterson West, LLC, regarding a newly-formed entity, Masterson West II, LLC (MWII). Upon closing, Empire Petroleum will own up to a maximum of 50 percent of MWII if it delivers $18,000,000 with a proportionate decrease down to 25 percent of Masterson West II at the lower end of the range. These oil and gas properties are in Moore and Potter Counties in the Texas Panhandle. The wells to be included in the transaction chiefly target the Red Cave formation.

Empire Petroleum Corp. (EMPR), closed Monday's trading session at $0.2999, up 19.96%, on 20,635 volume with 10 trades. The average volume for the last 60 days is 4,105 and the stock's 52-week low/high is $0.04/$0.30.


Organigram Holdings, Inc. (OGRMF)

CFN Media Group, InvestorPlace, Wealth Daily, Cannabis Financial Network News and Money Morning reported earlier on Organigram Holdings, Inc. (OGRMF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Organigram Holdings, Inc.’s emphasis is on producing the highest quality, condition specific medical marijuana for patients in Canada. Its wholly-owned subsidiary, Organigram, Inc, is a licensed producer of medical marijuana in Canada.  Organigram’s head office, production facility, and Research and Development (R&D) are in Moncton, New Brunswick. The Company’s shares trade on the OTCQB.

Organigram Holdings has collaborations with healthcare experts and academic institutions. It invests in medical education, outreach, as well as research for the use of cannabinoids as a first line of treatment.   

Organigram provides a diverse variety of genetics and product kinds. These cater to the individual needs of each client. The Company offers a reliable supply of first-rate quality, industry-leading strains to match individuals’ personal needs.

Organigram Holdings is regulated by the Access to Cannabis for Medical Purposes Regulations (ACMPR).  All of the Company’s products are manufactured under strict controls and in conformance with the Good Production Practices of the MMPR, and the security directives as defined by the Office of Controlled Substances. All products are lab tested prior to packaging and sale.   

Organigram is undergoing a production-facility expansion. The expansion will more than triple the size of its operations. The multi-million-dollar project will meet the growing needs of its medical patient base, and prepare it for the legal, adult-recreational marijuana market. The highlights of Organigram’s plans include the addition of about 140 new employees by the end of 2018.

In addition, Organigram’s plans include a production-capacity increase from approximately 5,200 kilograms (kg) annually to greater than 25,000 kg annually. Moreover, plans include the acquisition of a third building at 55 English Drive for future expansion, next to the present campus.

Organigram Holdings is in the final stages of planting the remaining three of the sixteen three-tier Phase 3 cultivation rooms that have been licensed by Health Canada. In total, its Phase 3 expansion has boosted the Company's target dried flower equivalent production capacity from an estimated 22,000 kg/annum (Phases 1 and 2) to 36,000 kg/annum (Phases 1, 2 and 3).

Organigram Holdings has entered into a non-binding term sheet to acquire up to 25 per cent of alpha-cannabis Pharma GmbH (Alpha-Cannabis Germany [ACG]) located in Stadthagen, Germany. Upon the agreement being final, Organigram will provide ACG with dried cannabis flower and sweet leaf for conversion into extracts for the growing German medical cannabis market.

Furthermore, Organigram has recently received a "Permit to Export Cannabis" from Health Canada. This will permit it to start its first global shipments.

Recently, Organigram Holdings announced that it entered into a Letter of Intent (LOI) with Hyasynth Biologicals, Inc. (Montreal, Quebec). Organigram proposes to make a strategic investment in Hyasynth. The non-binding LOI also contemplates Organigram entering into an off-take agreement with Hyasynth Biologicals whereby Organigram can purchase a pre-defined quantity of a variety of cannabinoids or cannabinoid related production from Hyasynth on terms set out in such agreement.

Last month, Organigram Holdings and Eviana Health Corporation jointly announced that they entered into a non-binding term sheet. Organigram will make a considerable equity investment into Eviana.  The Term Sheet also contemplates Organigram entering into an offtake agreement with Eviana for up to 50 percent of the cannabidiol (CBD) production of Eviana for a period of five years. This is subject to adjustment based on Organigram’s equity interest in Eviana.

Earlier this month, Organigram announced that it entered into an LOI with Hiku Brands Company Ltd. Organigram (as an approved supplier to Manitoba Liquor & Lotteries (MBLL), will supply Hiku with up to 1,000 kg of premium cannabis products annually for the term of the three-year agreement. Hiku concentrates on building a portfolio of iconic, engaging cannabis brands, premier retail experiences, as well as handcrafted cannabis production.

Organigram Holdings, Inc. (OGRMF), closed Monday's trading session at $3.699872, up 7.84%, on 512,681 volume with 913 trades. The average volume for the last 60 days is 354,973 and the stock's 52-week low/high is $1.67/$4.60.


Creative Medical Technology Holdings, Inc. (CELZ)

Stockhouse, OTC Markets, InvestorsHub, and MarketWatch reported on Creative Medical Technology Holdings, Inc. (CELZ), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc.  (CMT) is a clinical stage stem cell company listed on the OTCQB. Its focus is on Urology and Neurology utilizing stem cell treatments.  CMT and its affiliate company, Creative Medical Health, Inc., have centered on regenerative medical solutions for unmet Urological and Neurological needs since 2011.  The Company has a patent portfolio that encompasses all treatments.  CMT is based in Phoenix, Arizona. 

Through its own research and collaborations with top academic institutions, CMT has acquired a pioneering stem cell (AmnioStem) and developed proprietary protocols. Additionally, the Company has built an extensive intellectual property (IP) portfolio, developed complete treatment offerings for erectile dysfunction (ED), and launched a 40-patient trial for ED at UCLA.  Moreover, CMT is making advances for treating stroke using its newly acquired amniotic fluid-based stem cell.  

AmnioStem is Amniotic fluid derived stem cell. The AmnioStem patent covers means to isolate, grow, and use amniotic fluid derived stem cells in a scalable and commercializable manner. The AmnioStem™ stem cell is covered by an issued U.S. Patent, which was exclusively licensed from the University of California by CMT in 2016.

AmnioStem therapy is a practical protocol for producing therapeutic quality stem cells starting from a small (1-5 ml) amniocentesis sample.  AmnioStem cells do not require matching with the recipient, as one size fits all.  

CMT has its StemSpine™ initiative. This is a treatment designed to reverse the affects of atherosclerosis (the underlying disease that causes disc degeneration). The Company’s solutions include Caverstem™ for Erectile Dysfunction (ED).  

In February of this year, CMT announced the formation of CerebroStem LLC. This majority-owned subsidiary concentrates on developing stem cell therapies for brain injuries and neurodegenerative diseases. The Company's initial focus will be treating radiation induced brain damage.

In June, Creative Medical Technology announced the creation of CaverStem International LLC, a majority-owned subsidiary centered on commercializing stem cell therapy for erectile dysfunction to worldwide physicians and their patients. The Company is offering the Caverstem™ technology to selected physicians in the United States that qualify according to Creative Medical Technology's criteria.

Earlier this month, Creative Medical Technology announced the initiation of a program targeted at treating cancer associated wasting, via the in-licensing of patent application #15/814284 entitled "Treatment of Cachexia Using Stem Cells and Products Thereof”. The Company recently announced data that the AmnioStem™ stem cell was superior to other stem cell types at lessening inflammatory mediators, including TNF-alpha.

Also, in July, Creative Medical Technology announced that subsidiary Caverstem International signed an exclusive contract with Promo Med Russia for the commercialization of its CaverStem™ technology.

Creative Medical Technology Holdings, Inc. (CELZ), closed Monday's trading session at $0.04033, up 0.32%, on 8,765,926 volume with 270 trades. The average volume for the last 60 days is 22,341,305 and the stock's 52-week low/high is $0.0021/$0.27.


Northwest Biotherapeutics, Inc. (NWBO)

RedChip, PureActionStocks,  Promotion Stock Secrets, Wall Street Corner, BUYINS.NET, WealthMakers, Wealthpire, CoolPennyStocks, StreetInsider, StockPicksNYC, Market Report, Pennybuster, The Street, FeedBlitz, AllPennyStocks,  BullRally, Marketbeat, InvestorPlace, Streetwise Reports, OTCPicks, and  SmallCapVoice reported earlier on Northwest Biotherapeutics, Inc. (NWBO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Northwest Biotherapeutics, Inc. is a biotechnology enterprise developing DCVax® personalized immune therapies for solid tumor cancers.  In the United States and Europe, the Company’s focus is on developing personalized immunotherapy products, on a cost-effective basis, designed to treat cancers more effectively than existing treatments. This is without toxicities of the kind associated with chemotherapies. Northwest Biotherapeutics has its corporate office in Bethesda, Maryland.

Northwest Biotherapeutics has a wide-ranging platform technology for DCVax dendritic cell-based vaccines. It is working to move ahead with many clinical programs, involving DCVax-L and DCVax-Direct.

Northwest’s lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). This trial has completed its enrolment.  The Company is pursuing completion of the present Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer and pursuing Phase II combination trials of DCVax-L and checkpoint inhibitor drugs. This includes the Phase II trial of DCVax-L and Pembrolizumab (Keytruda) for colon cancer that was earlier announced.

The Company’s product candidates also include DCVax-Prostate. The design of this product is purposely for late stage, hormone independent prostate cancer. Northwest has developed a DCVax product line using a particular proprietary antigen — PSMA (Prostate Specific Membrane Antigen). It is found on essentially all late stage (hormone independent) prostate cancer. The PSMA is produced via recombinant manufacturing methods. It is subsequently combined with the fresh, personalized dendritic cells to make DCVax-Prostate.

Northwest Biotherapeutics earlier received clearance from the Food and Drug Administration  (FDA)  for a 612-patient Phase III trial in prostate cancer. It received approval in  Germany of a five-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.

In addition, the Company is pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed the 40-patient Phase I portion of the trial. It is preparing the Phase II portion. Northwest previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer in association with the University of Pennsylvania.

In late May, Northwest Biotherapeutics announced the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research organization (CRO) managing the trial, tabulated by an independent statistical firm and published with 69 co-authors in the peer reviewed Journal of Translational Medicine (JTM).

The reported data are from the most recent previous full data collection in 2017.  Northwest Biotherapeutics is undertaking another complete data collection. This is a multi-month process and will be continuing over the coming months.

Northwest Biotherapeutics, Inc. (NWBO), closed Monday's trading session at $0.214, down 2.28%, on 1,099,032 volume with 153 trades. The average volume for the last 60 days is 2,089,615 and the stock's 52-week low/high is $0.155/$0.398.


CurAegis Technologies, Inc. (CRGS)

InvestorsHub and OTC Markets reported on CurAegis Technologies, Inc. (CRGS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CurAegis Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The Company consists of two independent divisions - its CURA Division and its Aegis Division.  CurAegis is currently centering on commercialization strategies in different technologies. These include the CURA system, which includes the myCadian™ watch that measures degradation of alertness and sleep attributes; the Z-Coach e-learning education and training tool, and the Aegis hydraulic pump. CurAegis Technologies is based in Rochester, New York.

The CURA System comprises hardware and software that measures many metrics to establish that a person's ability to perform a task or job appears to be degrading. The CURA division is developing a proprietary technology and family of products designed to measure the decrease in a person’s alertness and to train persons on how to improve alertness levels. The CURA™ system and the myCadian™ watch enable the user and third parties to anticipate and prevent undesired or disastrous situations caused by the degradation of alertness.

CurAegis Technologies completed its validation studies of the CURA System at the University of Colorado at Boulder and the University of Rochester Medical Center. The Company earlier said that it can now state that it can predict a person’s fatigue level, at close to laboratory accuracy, in real-time.

The Z-Coach e-learning tool was acquired by CurAegis Technologies in September of 2015. The first of six Z-Coach e-learning modules, Z-Coach Aviation, was designed for aviation professionals.

Additionally, the Company’s Aegis hydraulic pump (Aegis Division) is an innovative hydraulic design. Its goal is to deliver better efficiencies in a package that is smaller and lighter than contemporary technologies.

Regarding the Aegis Division’s Aegis Pump and Motor, it has eliminated the rotating piston group (the cylinders are stationary). This makes the pump very robust and easy to manufacture. The Company’s patented valving has been integrated to increase efficiencies at peak and off peak operation.

Concerning the CURA System, CurAegis Technologies is on schedule to have its system set for shipments in Q3. Moreover, concerning Aegis Pumps and Motor, the new motor is in development and the Company’s prototype is scheduled to be available this month.

CurAegis Technologies, Inc. (CRGS), closed Monday's trading session at $0.29, up 10.69%, on 16,500 volume with 5 trades. The average volume for the last 60 days is 31,934 and the stock's 52-week low/high is $0.20/$0.76.


PharmaCyte Biotech, Inc. (PMCB)

OTCJournal,  PennyStockLaboratory, SmallCapNetwork, Cannabis Financial Network News, BUYINS.NET, MyBestStockAlerts, InvestorPlace, Goldman Small Cap Research, Damn Good Penny Picks,  Penny Picks, Darth Trader, Wall Street Corner, Penny Stock General, PennyStockInformer, Fast Money Alerts, Penny Stock Beats, Stock Shock and Awe, The Stock Psycho, and Stock Market Media Group reported earlier on PharmaCyte Biotech, Inc. (PMCB), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

PharmaCyte Biotech, Inc. focuses on developing targeted treatments for cancer and diabetes applying its signature live cell encapsulation technology, Cell-in-a-Box®. This unique and patented technology is being utilized as a platform upon which treatments for many kinds of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. A clinical stage biotechnology company, PharmaCyte Biotech has its corporate headquarters in Silver Spring, Maryland.

The OTCQB-listed Company is also working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other kinds of solid cancerous tumors.  PharmaCyte’s  treatment for pancreatic cancer involves low doses of the recognized anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. 

The capsules are placed as close to the cancerous tumor as possible. This is to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. The live-cell encapsulation technology that the Company employs is a way to enclose living cells in protective “cocoons” roughly the size of the head of a pin. It encapsulates living cells, not drugs.

Each capsule can enclose about 10,000 cells. This number can differ depending upon the size of the cells encapsulated. PharmaCyte Biotech is advancing its new treatment for pancreatic cancer into the clinic in the United States, with study sites in Europe and Australia.

Additionally, the Company is  developing treatments for cancer based upon chemical constituents of the Cannabis  plant, named cannabinoids.  It is studying ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects typically associated with cancer treatments.
In June, PharmaCyte Biotech announced that it successfully completed the comprehensive characterization of its proprietary cell clone known as 22P1G.

The 22P1G cells constitute the cells in the Master Cell Bank (MCB), which were prepared and tested by the Company’s contractor, Eurofins Lancaster Laboratories.

The cells from the MCB will serve as the active pharmaceutical ingredient (API) in PharmaCyte’s Cell-in-a Box® capsules, which will be used (together with low doses of the cancer prodrug ifosfamide) for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) in the Company’s planned clinical trial.

Last week, PharmaCyte Biotech announced that it successfully completed a study on the stability after “hand thawing” syringes of the Cell-in-a-Box® encapsulated cells. The data obtained from this “hand thawing” study is compulsory by the U.S. Food and Drug Administration (FDA).

The results of the “hand thawing” study announced show that the viability of the cells remains essentially the same for a minimum of 30 minutes at room temperature. This serves to define the time that the interventional radiologist has to implant the Cell-in-a-Box® capsules after thawing to ensure cellular viability within the patient.

PharmaCyte Biotech, Inc. (PMCB), closed Monday's trading session at $0.0596, down 5.40%, on 2,554,210 volume with 118 trades. The average volume for the last 60 days is 3,258,540 and the stock's 52-week low/high is $0.0302/$0.105.


eWellness Healthcare Corp. (EWLL)

InvestorsHub, Stockhouse, StockHideout, Penny Stock Prodigy, and 4-Traders reported on eWellness Healthcare Corp. (EWLL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, eWellness Healthcare Corp. develops a telemedicine platform. This platform is for providing Distance Monitored Physical Therapy programs. The programs are for pre-diabetic, cardiac, and health challenged patients via contracted physician practices and healthcare systems. eWellness Healthcare is based in Culver City, California.

The Company has launched PHZIO. The design of this Physical Therapy Telemedicine platform is to extend and scale a physician’s practice. eWellness Healthcare is the first physical therapy telemedicine enterprise to provide insurance reimbursable real-time distance monitored treatments.  

eWellness Healthcare’s PHZIO extends a traditional practice online. The chief features of the PHZIO platform include video treatment protocols, real-time patient monitoring, patient induction forms, a patient video journal, and post treatment evaluations.

Additionally, chief features include integrated billing, patient metrics, and user administration & customization. Furthermore, PHZIO scales a practice’s billable rates and provides tools to make developing a business easier.

Regarding the Patient Dashboard, the PHZIO Dashboard allows clients to login securely to access prescribed treatment protocols. PHZIO is user-friendly and highly reliable to operate for PT and Patient. Moreover, it is a comprehensive on-line PT telemedicine intervention system.

eWellness Healthcare’s business model is to license the PHZIO platform to any Physical Therapy (PT) clinic in the U.S. and/or have large-scale employers use its PHZIO platform as a totally PT monitored corporate wellness program. 

The Company has launched its new patient lead generation platform, Lead Remedy increases a Practices’ social networks reach through tapping into the employees of the practice and their social circles.

eWellness Healthcare announced this past April that it is developing the first tokenized physical therapy payment system for insurance companies, large scale self-insured corporations, and their insured members. Fintech Global Consultants will assist eWellness Healthcare in completing the Blockchain and tokenized payment system.

The anticipation is that eWellness Healthcare’s PHZIO Treatment Platform utilization will expand because of the new Physical Therapy Licensure Compact.

Mr. Darwin Fogt, eWellness Healthcare Chief Executive Officer, said, “The purpose of the compact is to increase consumer access to physical therapy services by reducing regulatory barriers to interstate mobility and cross–state practice. Our PHZIO platform is the Physical Therapy Treatment Disrupter.”

Moreover, the anticipation is that eWellness Healthcare’s PHZIO Treatment Platform utilization will expand because of the new Physical Therapy Workman’s Compensation Partnerships, which are in the works.

Mr. Fogt said, ““The purpose of the new Physical Therapy Workman’s Compensation Partnerships is to increase consumer access to our digital PT services platform.”

eWellness Healthcare Corp. (EWLL), closed Monday's trading session at $0.0721, down 3.87%, on 1,511,703 volume with 119 trades. The average volume for the last 60 days is 387,192 and the stock's 52-week low/high is $0.05/$0.1925.


Kalytera Therapeutics, Inc. (KALTF)

The Street, OTC Markets, InvestorsHub, Stockhouse, Stockwatch, Dividend Investor, and Investing reported on Kalytera Therapeutics, Inc. (KALTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kalytera Therapeutics, Inc. is pioneering the development of a next generation of cannabinoid therapeutics. The Company is working to establish a leading position in the development of novel cannabinoid medicines for an array of important unmet medical needs, with an initial emphasis on Graft versus Host Disease (GvHD). A clinical-stage pharmaceutical company, Kalytera Therapeutics has its U.S. headquarters in Novato, California. The Company’s research facility is in Israel.

Kalytera Therapeutics is also developing a new class of proprietary cannabidiol (CBD) therapeutics. Kalytera’s intention is to explore the use of CBD, a non-psychoactive cannabis constituent.

The Company is working to advance a portfolio of synthetic, non-psychoactive cannabis-like molecules. In addition, Kalytera will concentrate on orphan conditions, with the goal of generating data in humans that may support follow-on studies in major conditions.

Kalytera Therapeutics has received approval from the Institutional Review Board (IRB) at one of two clinical sites in Israel. This is to begin a Phase 2 study to evaluate cannabidiol (CBD) for the prevention of GvHD. The proposed study is a Phase 2, open label, multicenter trial.

This trial is to evaluate the pharmacokinetic profile, safety, and efficacy of multiple doses of CBD for the prevention of GvHD following allogeneic hematopoietic cell transplantation (HCT). The proposed study will take place at the Rabin Medical Center, Beilinson, and the Rambam Health Care Campus, Haifa, in Israel.

GvHD is a multisystem disorder. It is a common, life-threatening complication of hematopoietic stem cell transplant (HCT) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs. This includes the skin, gastrointestinal tract, liver, lungs, as well as eyes.

Kalytera Therapeutics’ continuing Phase 2b clinical study evaluating the use of CBD in the prevention of GVHD is expected to be completed early 2019. The Company has enrolled patients at clinical sites in Israel. To speed up the enrollment process the Company is in the process of expanding the study to include two additional sites in Australia. Upon completion of the Phase 2b clinical study, Kalytera will commence preparations for the pivotal Phase 3 clinical study that will be required for FDA approval.

Earlier this month, Kalytera Therapeutics announced it will meet with the Center for Drug Evaluation and Research (CDER) of the FDA on Tuesday, July 31, 2018. The meeting is to discuss manifold aspects of the Company’s planned registration study evaluating cannabidiol (CBD) for the treatment of acute graft versus host disease (GVHD).

Additionally, this month, Kalytera announced that it entered into an agreement with Beetlebung Pharma, Ltd. (BPL) for an option to acquire all rights to medical cannabis products in development by BPL for the treatment of dermatologic diseases and women's health.

With this agreement, Kalytera will have the option to license from BPL certain proprietary medical cannabis formulations that can initially be brought to market in jurisdictions that have already approved access to cannabis for medical purposes. Kalytera Therapeutics’ belief is that this will provide a more near-term path to revenues, versus the lengthier process required for commercialization following FDA approval.

Kalytera Therapeutics, Inc. (KALTF), closed Monday's trading session at $0.09, up 8.43%, on 513,137 volume with 74 trades. The average volume for the last 60 days is 260,574 and the stock's 52-week low/high is $0.06/$0.4544.



MarketWatch, TradingView, and Bloomberg reported on FISION Corp. (FSSN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

iFISION Corp. is a cloud-based digital asset management and marketing automation company headquartered in Minneapolis, Minnesota. The Company serves enterprise clients in the health care, hospitality, financial/insurance, software, and technology industries. FISION has more than 65,000 users in 21 countries. Established in 2011, FISION lists on the OTC Markets Group’s OTCQB.

FISION is an effective sales enablement and marketing asset management tool. It maximizes the brand potential of every sales interaction. The Company’s advanced, proprietary technology specializes in managing customers’ brand and marketing content. This enables marketing and sales people to quickly and easily create compelling, personalized, on-brand communications, which increases revenue and profits.

FISION’s solutions include simplified brand distribution, sales enablement, distributed & localized marketing, digital asset management, channel support, and measurement & analytics. The Company equips marketing and sales teams with a comprehensive set of enablement capabilities built to solve distributed marketing challenges. Concerning digital asset management, FISION’s centralized, cloud-based library supports close to 200 different file kinds and gives a client total control over how company assets are stored, retrieved, and used.

FISION has completed the acquisition of Volerro Corporation (Minneapolis, Minnesota-based) following the announcement of a definitive purchase agreement on April 25, 2017. Volerro is a leader in cloud-based content collaboration and agile marketing technology.

Volerro enhances the FISION platform with complementary cloud-based collaboration, agile marketing, and sales enablement software. Volerro’s SaaS (Software as a Service) platform simplifies how enterprise teams create, refine, and distribute content.

Recently, FISION was awarded a U.S. patent (US9639551 B2) covering its cloud-based marketing technology called, “Computerized Sharing of Digital Asset Localization Between Organizations.”

FISION Chief Executive Officer, Mr. Mike Brown, said, “Our patented platform’s unique multi-tiered and multi-tenant functionality permits outside agencies and other marketing partners to securely access a company’s content repository, and create collateral materials that stays true to approved branding and messaging. It also provides administrators real-time visibility into the effectiveness of marketing and sales communication, measuring performance down to the individual asset and user level.”

FISION Corp. (FSSN), closed Monday's trading session at $0.161, up 4.41%, on 128,555 volume with 24 trades. The average volume for the last 60 days is 191,919 and the stock's 52-week low/high is $0.0811/$0.26.


Gratitude Health, Inc. (GRTD)

MarketWatch, Cannabis Daily, Wallet Investor, Simply Wall St, Investors Hangout, InvestorsHub, Morningstar, Stockhouse, Barchart, GuruFocus, and TradingView reported on Gratitude Health, Inc. (GRTD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gratitude Health, Inc. manufactures, sells, and markets functional ready to drink beverages under the Gratitude brand. The Company’s Founders, Mr. Roy Warren and Mr. Andy Schamisso, are beverage veterans with greater than thirty years of experience in the industry. Gratitude Health was conceived to manufacture healthy, inventive, and certified-organic beverages for a consumer market interested in healthy aging.

Formed in 2017, Gratitude Health has its corporate office in North Palm Beach, Florida. The Company lists on the OTC Markets Group’s OTCQB.

Gratitude Health offers flavored and unsweetened ready to drink teas. Its alternative food and beverage options are nutrient rich. They feature reduced or eliminated carbohydrate and sugar levels. In addition, they are full of anti-oxidants and organic ingredients.

Each bottle contains no more than 45 calories. The Company’s 16 oz proprietary bottles feature collectible debossed designs intended to be reused and repurposed.

Gratitude Health pan-roasts its tea by hand. Its tea flavors include Dragon Well Green Tea Peach; Dragon Well Green Tea Mint; Dragon Well Green Tea Wildberry; Dragon Well Green Tea Blood Orange; and Dragon Well Green Tea Original.

Dragon Well tea (culturally known as "Longjing") comes from the pristine, certified-organic fields of Hangzhou China. Dragon Well tea has the distinction of being named "The Tea of Emperors". It is the most popular in China.

The Company’s routes to market include Direct-to-Retail sales; Direct Store Delivery (DSD); and Direct-to-Consumer sales through the Internet.

In April of this year, Gratitude Health announced that it entered into a definitive exchange and spinoff agreement with Vapir Enterprises, Inc., previously traded under the symbol VAPI. The combination facilitated Gratitude Health, Inc. to become a publicly traded company.

With the agreement, Vapir Management will retain its operations, intellectual property (IP), assets, and liabilities. It will continue as a separate operating entity and will not be involved in the beverage business.  Vapir is a developer and manufacturer of vaporization devices.

This past May, Gratitude Health announced the appointment of three new Independent Directors. It named Mr. Jack Shea of Mamaroneck, New York; Mr. Mike Edwards of Stuart, Florida; and Mr. Bruce J. Zanca of Jupiter, Florida as Directors.

Mr. Shea will serve as Chairman of the Compensation Committee. Mr. Edwards will chair the Audit Committee.  Mr. Zanca will serve as Chairman of the Board's Compliance Committee.

Gratitude Health, Inc. (GRTD), closed Monday's trading session at $0.05, even for the day, on 94,380 volume with 17 trades. The average volume for the last 60 days is 49,738 and the stock's 52-week low/high is $0.012/$0.785.


The QualityStocks Company Corner

Consorteum Holdings, Inc. (OTC: CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH).

Consorteum Holdings, Inc. (OTC: CSRH) Universal Mobile Interface™ (UMI) platform is able to integrate any stream of data onto a mobile platform while delivering and managing mobile connectivity. In addition, the UMI provides secure transactional processing and social connectivity to create a more personalized mobile experience.

Consorteum Holdings, Inc. (OTC: CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company’s commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ (“UMI”) solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company’s UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum’s wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company’s UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI’s technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum’s primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum’s management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum’s management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors.

Consorteum Holdings, Inc. (CSRH), closed the day's trading session at $0.0019, up 11.76%, on 1,803,735 volume with 19 trades. The average volume for the last 60 days is 6,613,964 and the stock's 52-week low/high is $0.0005/$0.0085.

Recent News


ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF).

Globally licensed cannabis company ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the introduction of FIRESIDE, its first recreational cannabis brand. To view the full press release, visit:

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” ABcann Global CEO Barry Fishman said.

ABcann Global owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

ABcann has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by ABcann’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting ABcann’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

ABcann’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with ABcann’s philosophy of quality and innovation.

ABcann’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, ABcann also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

ABcann Global (ABCCF), closed the day's trading session at $0.901, up 6.25%, on 246,051 volume with 195 trades. The average volume for the last 60 days is 215,539 and the stock's 52-week low/high is $0.65/$3.2929.

Recent News


Medical Cannabis Payment Solutions (OTC: REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Cannabis-focused financial services company Medical Cannabis Payment Solutions (OTC: REFG) recently partnered with Paper Lantern, LLC to create the nation’s largest mobile hemp CBD processing service. To view the full article, visit:

Medical Cannabis Payment Solutions (OTC: REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.042, up 6.87%, on 157,396 volume with 32 trades. The average volume for the last 60 days is 535,509 and the stock's 52-week low/high is $0.0161/$0.092.

Recent News


SinglePoint, Inc. (OTCQB: SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint, Inc. (OTCQB: SING) was a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program discussing “money and what makes it happen.” To view the full interview, visit: To view the full press release, visit:

SinglePoint, Inc. (OTCQB: SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.039, up 1.77%, on 1,850,071 volume with 146 trades. The average volume for the last 60 days is 7,088,967 and the stock's 52-week low/high is $0.0235/$0.415.

Recent News


Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

NetworkNewsWire released a report on the company detailing how vertically integrated cannabis company Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) has announced an agreement to produce top-quality cannabis extracts for Cannabis Strategic Ventures, Inc. (OTC: NUGS) (

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $4.32, up 0.82%, on 35,314 volume with 97 trades. The average volume for the last 60 days is 41,665 and the stock's 52-week low/high is $4.14/$16.00.

Recent News


Pacific Software, Inc. (OTC: PFSF)

The QualityStocks Daily Newsletter would like to spotlight Pacific Software, Inc. (PFSF).

Emerging development technology corporation Pacific Software (OTC: PFSF) this morning announced that it has engaged the corporate communications expertise of NetworkNewsWire (“NNW”). To view the full press release, visit: Also today, NetworkNewsWire released a report on the company detailing how PFSF’s blockchain technologies have been designed to increase supply chain transparency, increasing consumer confidence. To view the full article, visit:

Pacific Software, Inc. (OTC: PFSF) is focused on the design, development, and distribution of Hyperledger blockchain technology solutions for application to the specific needs of agriculture, cannabis, and the opioid epidemic.

The basic requirements of the systems to be developed include high-throughput transaction processing, traceability or tracking, visibility or monitoring, and transparency throughout the supply and value chains for the stakeholders. The development of this architecture will serve as an online commercial portal to service Pacific Software’s B2B accounts in the sectors below.

For application of its Agri-blockchain based system, Pacific Software will target farm-to-consumer exports to increase transparency, combat theft and counterfeit products, and reduce the health risks associated with shipping “tainted” agricultural products to other countries.

Perceiving blockchain as an ideal mechanism for the complexities of the cannabis industry, Pacific Software will strive to improve the transparency, compliance, and efficiency of the “seed-to-sale” supply chain in states where the plant is legal.

Controlled Substances
With the misuse of opioids on the rise worldwide, Pacific Software aims to apply its blockchain-based system to track opioids from pharmaceutical production to consumers and attempt to identify “Bad Actors” in the supply chain and fight against the global epidemic.

Business Model
The portal will be structured in a B2B format where clients will pay the company transaction fees, royalties, cash, cash equivalents and other forms of compensation to utilize its Hyperledger blockchain applications for their business models.

As the company executes these strategies, each Hyperledger blockchain-based system designed may be organized separately in wholly owned subsidiaries. To enhance its portfolio of holdings, Pacific Software may consider investments in companies where selected markets have imminent profitable results, providing appreciable value for investors and shareholders.

Pacific Software, Inc. (PFSF), closed the day's trading session at $4.00, even for the day. The average volume for the last 60 days is 47 and the stock's 52-week low/high is $4.00/$4.00.

Recent News

chart (OTCQB: CIIX)

The QualityStocks Daily Newsletter would like to spotlight (CIIX)., Inc. (OTCQB: CIIX) CEO Warren Wang said in a recent SmallCapVoice interview that he expects to expand CIIX’s previously announced ATM network to eventually include the Canadian cities of Vancouver and Toronto. Focusing on international growth, he also announced that the company will offer its Bitcoin Trading Academy online courses in Asia to reach a larger audience (

Founded in 1999, (OTCQB: CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website,, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site,, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. (CIIX), closed the day's trading session at $0.38, off by 1.30%, on 47,467 volume with 22 trades. The average volume for the last 60 days is 59,847 and the stock's 52-week low/high is $0.365/$1.58.

Recent News


Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Fully integrated oil and gas company Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is boosting its footprint within the Utah Oil Sands Region where the company’s Asphalt Ridge facility is located, CEO David Sealock stated in a recent news release ( The company has signed a letter of intent to pursue additional acreage and resources within the state from Mareton Alliance LP, meeting a key initiative that Petroteq has been pursuing this year.

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil and gas exploration and production on mineral leases it owns in Texas with Accord GR Energy Inc. and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ, the Company’s collaboration formed with First Bitcoin Capital Corp. (OTC: BITCF). PetroBLOQ’s novel blockchain-based oil and gas supply chain management platform is currently being co-developed by the two companies.

PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy CEO Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry. “API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 3,000-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Liquid Extraction System.

The company’s Texas location includes an ownership interest (46%) in 7,000 acres under mineral leases with Accord, a Houston-based oil and gas exploration company that focuses on the development and recovery of heavy oil reserves and deposits. Two enhanced, licensed oil recovery technologies designed to increase oil recovery from more than 80 shallow oil wells on the property are expected to substantially improve the recovery rates of heavy oil deposits in this area. In both the Utah oil sands and traditional oil patch Texas project, the Company, its subsidiaries and Accord are using proprietary technologies, processes and methodologies to recover heavy oil, providing a distinct, strategic economic advantage for Petroteq Energy and its shareholders.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy Inc. (PQEFF), closed the day's trading session at $0.87, off by 2.24%, on 439,690 volume with 294 trades. The average volume for the last 60 days is 218,103 and the stock's 52-week low/high is $0.28/$1.8892.

Recent News


First Cobalt Corp. (TSX-V: FCC) (OTCQX: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) (ASX: FCC) is reaping rewarding reports from its exploration to extend a historic resource in Idaho’s prolific Cobalt Belt. The project is an example of industry efforts to establish North American sources of the metal so vital to high-tech batteries and other modern tech applications, and First Cobalt’s portfolio indicates its potential in leading the effort. Having stable North America-based operations and sources could help avoid unpredictable future problems, such as Panasonic’s recent sudden cut off of a cobalt supplier due its relationship with Cuba.

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.2728, off by 2.57%, on 337,829 volume with 114 trades. The average volume for the last 60 days is 220,472 and the stock's 52-week low/high is $0.242/$1.3041.

Recent News


Cannabis Strategic Ventures, Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

NetworkNewsWire released a report on Cannabis Strategic Ventures, Inc. (OTC: NUGS) detailing how, through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. Also today, NetworkNewsWire discussed the production supply agreement announced with vertically integrated cannabis company Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF).

Cannabis Strategic Ventures, Inc. (OTC: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $1.98, off by 7.91%, on 19,315 volume with 45 trades. The average volume for the last 60 days is 34,740 and the stock's 52-week low/high is $0.031/$7.13.

Recent News


PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

Now that some 44 nations around the globe have passed laws allowing marijuana for medical use, the market is set for rapid expansion in the coming years. Industry analysts Grand View Research estimate that the global medical marijuana market will reach a value of $55.8 billion by 2025, as the range of therapies for cannabis multiplies ( Much of this expected demand will be driven by treatments for chronic pain, but applications are also likely to be developed for a number of other ailments, such as anxiety, epilepsy, multiple sclerosis (MS) and post-traumatic stress disorder (PTSD), that appear to benefit from cannabis prescription. As a result of these developments, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has launched a medicinal cannabis division that will also advance the company’s vision of becoming a global preventive health care company.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.028, off by 11.95%, on 931,535 volume with 95 trades. The average volume for the last 60 days is 555,393 and the stock's 52-week low/high is $0.002/$0.20.

Recent News


Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

CryptoNewsAudio announces the Audio Press Release (APR) titled "Acid Test for Cryptos and Blockchain Tech Increasingly about 'Spendability' and Usability," featuring Virtual Crypto Technologies Inc. (OTCQB: VRCP). To hear the CryptoNewsAudio version, visit To read the original editorial, visit

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website,, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

  • Downloadable NetoBit Trader app link and contact forms for more information
  • MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
  • Improved security utilizing https certificates to protect personal information and site integrity
  • Media room with downloadable product brochures, corporate presentations and other relevant content
  • Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
  • Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.0827, off by 19.71%, on 9,129 volume with 7 trades. The average volume for the last 60 days is 34,661 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.